[go: up one dir, main page]

DE69735383D1 - Methode zur Inhibierung von HEREGULIN und seines Rezeptors sowie Verwendung zur Inhibierung von Krebszellen - Google Patents

Methode zur Inhibierung von HEREGULIN und seines Rezeptors sowie Verwendung zur Inhibierung von Krebszellen

Info

Publication number
DE69735383D1
DE69735383D1 DE69735383T DE69735383T DE69735383D1 DE 69735383 D1 DE69735383 D1 DE 69735383D1 DE 69735383 T DE69735383 T DE 69735383T DE 69735383 T DE69735383 T DE 69735383T DE 69735383 D1 DE69735383 D1 DE 69735383D1
Authority
DE
Germany
Prior art keywords
image
compounds
pct
inhibiting
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69735383T
Other languages
English (en)
Other versions
DE69735383T2 (de
Inventor
Dajun Yang
Shaomeng Wang
Alan P Kozikowski
Marc E Lippman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of DE69735383D1 publication Critical patent/DE69735383D1/de
Application granted granted Critical
Publication of DE69735383T2 publication Critical patent/DE69735383T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69735383T 1996-11-19 1997-11-19 Methode zur Inhibierung von HEREGULIN und seines Rezeptors sowie Verwendung zur Inhibierung von Krebszellen Expired - Fee Related DE69735383T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3136896P 1996-11-19 1996-11-19
US31368P 1996-11-19
PCT/US1997/021474 WO1998021956A1 (en) 1996-11-19 1997-11-19 Heregulin antagonists and methods for their use

Publications (2)

Publication Number Publication Date
DE69735383D1 true DE69735383D1 (de) 2006-04-27
DE69735383T2 DE69735383T2 (de) 2007-02-15

Family

ID=21859076

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735383T Expired - Fee Related DE69735383T2 (de) 1996-11-19 1997-11-19 Methode zur Inhibierung von HEREGULIN und seines Rezeptors sowie Verwendung zur Inhibierung von Krebszellen

Country Status (7)

Country Link
US (1) US6143740A (de)
EP (1) EP0944311B1 (de)
JP (1) JP2001504830A (de)
AT (1) ATE318515T1 (de)
AU (1) AU5588598A (de)
DE (1) DE69735383T2 (de)
WO (1) WO1998021956A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008001720A (ja) * 2002-06-21 2008-01-10 Japan Science & Technology Agency アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
ES2616047T3 (es) 2004-05-03 2017-06-09 Merrimack Pharmaceuticals, Inc. Liposomas útiles para la administración de fármacos
US10456360B2 (en) 2015-10-16 2019-10-29 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795568C3 (de) * 1964-07-31 1974-07-18 Gruppo Lepetit S.P.A., Mailand (Italien) 3-Hydroxymethyl-rifamycin SV und Verfahren zu seiner Herstellung. Ausscheidung aus: 1595883
FR208F (de) * 1964-07-31
IT1046627B (it) * 1970-06-01 1980-07-31 Lepetit Spa Composizioni antivirali contenenti derivati della rifaumicina sv
US4005076A (en) * 1971-06-24 1977-01-25 Gruppo Lepetit S.P.A. Hydrazones of 3-formylrifamycin SV
AR207763A1 (es) * 1973-07-25 1976-10-29 Archifar Ind Chim Trentino Metodo para la preparacion de 1,3-oxacino(5,6-c)rifamicinas
GB8318072D0 (en) * 1983-07-04 1983-08-03 Lepetit Spa Water-soluble rifampicin derivatives
GB8408924D0 (en) * 1984-04-06 1984-05-16 Dobfar Spa 3-azinomethyl rifamycins
US4681938A (en) * 1984-08-27 1987-07-21 Ciba-Geigy Corporation Novel polycyclic hydrazones of rifamycins, their manufacture, and their pharmaceutical compositions for treating tuberculosis
US4774237A (en) * 1986-02-14 1988-09-27 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Expellants of phytopathogenic microbes
US5095108A (en) * 1990-08-28 1992-03-10 Technologichen Kombinat Za Promishlena Microbiologia Non-solvated crystalline form "A" of 3-(4-cynnamyl-1-piperazinyl)iminomethylrifamycine SV and a method of its production
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin

Also Published As

Publication number Publication date
DE69735383T2 (de) 2007-02-15
ATE318515T1 (de) 2006-03-15
US6143740A (en) 2000-11-07
JP2001504830A (ja) 2001-04-10
WO1998021956A1 (en) 1998-05-28
EP0944311A4 (de) 2001-09-12
EP0944311B1 (de) 2006-03-01
EP0944311A1 (de) 1999-09-29
AU5588598A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
BR9910297A (pt) Novos análogos graxos para o tratamento de diabetes
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
ATE220400T1 (de) Trizyklische verbindungen zur behandlung von zellproliferativen störungen
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
ES2194987T3 (es) Compuestos triciclicos utiles para inhibir la farnesil-protein-transferasa.
ATE194620T1 (de) N-substituierte azabicycloalkanderivate als neuroleptika usw.
ATE357434T1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
ES8708232A1 (es) Procedimiento para la produccion de derivados de la 13-beta-milbemicina
NZ539254A (en) Stabilized pharmaceutical composition containing basic excipients
UA48937C2 (uk) Імідазолідини, заміщені гетероциклом, спосіб їх одержання і фармацевтична композиція, що їх містить
BR9507929A (pt) Composto de 4-aril-1-(inano-metil di-hidro-benzo-furano- metil ou di-hidro-benzo-tiofeno-metil) -piperidina -terra-hidro- piridina ou -piperazina composiç o farmacêutica e uso do composto
BRPI0507054A (pt) bloqueadores do canal de cálcio tipo n
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
AU2003285454A1 (en) Hair treatment composition containing a styryl-pyrazole compound
DE69735383D1 (de) Methode zur Inhibierung von HEREGULIN und seines Rezeptors sowie Verwendung zur Inhibierung von Krebszellen
GR3020330T3 (en) Novel bicyclic pyrimidine compounds, method for preparing same and pharmaceutical compositions containing said compounds.
IL165220A0 (en) Novel compounds, their use and preparation
ATE205194T1 (de) Alpha-(pyrazol-3-yl)-oxymethylen- phenylbutensäuremethylester und ihre verwendung zur bekämpfung von schadpilzen oder tierischen schädlingen
DE3567210D1 (en) Isoindolinone derivatives, production and use thereof
ES8404151A1 (es) Procedimiento para la preparacion de nuevos derivados de acidos (di)-tiofosforicos y fosfonicos.
BR9707266A (pt) Compostos dihidrobenzofurano úteis como agentes antiinflamatórios
ATE8049T1 (de) 1,3-dioxan-5-yl-alkyltriazole, ihre herstellung, ihre verwendung zur regulierung des pflanzenwachstums und mittel dafuer.
DE59604901D1 (de) Carbamoylcarbonsäureamide
DE60132324D1 (de) Substituierte caprolactam carbonate und ether sowie deren verwendung als anti-tumor wirkstoffe

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee